Immatics Biotechnologies Gmbh

Immatics Us, Inc.

Siemens Aktiengesellschaft

Steffen Walter

Toni Weinschenk

Harpreet Singh

Jens Fritsche

Norbert Hilf

Oliver Schoor

Peter Lewandrowski

Colette Song

Claudia Trautwein

Sabrina Kuttruff-Coqui

Dominik Maurer

Sebastian Bunk

Leonie Alten

Christian Brunhuber

Melinda Mata

Yannick Bulliard

Claudia Lemmel

Mamta Kalra

Ali Mohamed

Richard Matz

Stefan Denneler

Henning Hanebuth

Amir Alpert

Monique Dao

Sarah Missell

Susanna Mandruzzato

Niels Emmerich

Nobert Hilf

Zoe Coughlin

Agathe Bourgogne

Aleksandra Nowicka

Regina Mendrzyk

Vincenzo Bronte

Axel Papperitz

Moritz Fischle

Schoor Oliver

A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.

Immunotherapy against several tumors including gastrointestinal and gastric cancer

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Immunotherapy against neuronal and brain tumors

A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an WIC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

Immunotherapy against several tumors including lung cancer

A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.

The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

WPRE mutant constructs, compositions, and methods thereof

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Personalized immunotherapy against several neuronal and brain tumors

The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of &#x3b3;&#x3b4; T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of &#x3b3;&#x3b4; T cells while depleting &#x3b1;- and/or &#x3b2;-TCR positive cells. T cell populations comprising expanded &#x3b3;&#x3b4; T cell and depleted or reduced &#x3b1;- and/or &#x3b2;-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.

Methods for expanding and activating &#x3b3;&#x3b4; T cells for the treatment of cancer and related malignancies

Growing community of inventors

Reutlingen, Germany

Steffen Walter